Allogeneic Cellular Vaccine 1650-G

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.

**Synonyms:** - 1650-G - 1650-G Vaccine - 1650G